Skip to content

Qualigen picks up a bull who sees a two-bagger after release of COVID-19 test

August 25, 2020

Alliance Global Partners upgrades Qualigen (QLGN +4.0%) to Buy with a $10 (107% upside) price target. In a note, analyst James Molloy regards the company as a “compelling opportunity” in cancer detection and treatment.

It currently markets its FastPack System for detecting prostate cancer, thyroid function and metabolic disorders. It plans to launch the FastPack PRO SARS-CoV-2 IgG antibody test this quarter.

Lead therapeutic candidate is AS1411, a G-rich oligonucleotide that binds to a protein called nucleolin that is present on the surface of cancer cells.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: